DK475779A - Fremgangsmaade til fremstilling af membranproteiner ud fra neisseria meningitidis samt vaccine indeholdende saadanne membranproteiner - Google Patents

Fremgangsmaade til fremstilling af membranproteiner ud fra neisseria meningitidis samt vaccine indeholdende saadanne membranproteiner

Info

Publication number
DK475779A
DK475779A DK475779A DK475779A DK475779A DK 475779 A DK475779 A DK 475779A DK 475779 A DK475779 A DK 475779A DK 475779 A DK475779 A DK 475779A DK 475779 A DK475779 A DK 475779A
Authority
DK
Denmark
Prior art keywords
membrane proteins
neisseria meningitidis
procedure
vaccine containing
manufacturing
Prior art date
Application number
DK475779A
Other languages
English (en)
Other versions
DK154841C (da
DK154841B (da
Inventor
T B Helting
G Guthoehrlein
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of DK475779A publication Critical patent/DK475779A/da
Publication of DK154841B publication Critical patent/DK154841B/da
Application granted granted Critical
Publication of DK154841C publication Critical patent/DK154841C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK475779A 1978-11-11 1979-11-09 Fremgangsmaade til fremstilling af membranproteiner ud fra neisseria meningitidis DK154841C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19782848965 DE2848965A1 (de) 1978-11-11 1978-11-11 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
DE2848965 1978-11-11

Publications (3)

Publication Number Publication Date
DK475779A true DK475779A (da) 1980-05-12
DK154841B DK154841B (da) 1988-12-27
DK154841C DK154841C (da) 1989-06-05

Family

ID=6054405

Family Applications (1)

Application Number Title Priority Date Filing Date
DK475779A DK154841C (da) 1978-11-11 1979-11-09 Fremgangsmaade til fremstilling af membranproteiner ud fra neisseria meningitidis

Country Status (9)

Country Link
EP (1) EP0011243B1 (da)
JP (1) JPS5566519A (da)
AT (1) ATE857T1 (da)
AU (1) AU533386B2 (da)
CA (1) CA1142083A (da)
DE (2) DE2848965A1 (da)
DK (1) DK154841C (da)
ES (1) ES485715A1 (da)
IL (1) IL58673A (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317811A (en) 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
AU563317B2 (en) * 1982-12-02 1987-07-02 Rockefeller University, The Iga binding antibody
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7628995B2 (en) * 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2337309T5 (es) 2006-06-12 2013-07-30 Glaxosmithkline Biologicals S.A. Vacuna
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
WO2011024072A2 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
AU2018330322A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US12128094B2 (en) 2018-11-06 2024-10-29 Glaxosmithkline Biologicals Sa Immunogenic compositions comprising OMVs, an acellular pertussis antigen, a tetanus toxoid and a diphtheria toxoid
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115072D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Also Published As

Publication number Publication date
ATE857T1 (de) 1982-04-15
DK154841C (da) 1989-06-05
EP0011243B1 (de) 1982-04-14
IL58673A0 (en) 1980-02-29
AU5268279A (en) 1980-05-15
JPS5566519A (en) 1980-05-20
DE2962526D1 (en) 1982-05-27
JPS6350332B2 (da) 1988-10-07
IL58673A (en) 1983-02-23
ES485715A1 (es) 1980-05-16
CA1142083A (en) 1983-03-01
AU533386B2 (en) 1983-11-24
DE2848965A1 (de) 1980-05-22
DK154841B (da) 1988-12-27
EP0011243A1 (de) 1980-05-28

Similar Documents

Publication Publication Date Title
AU533386B2 (en) Isolation of membrane proteins from neisseria meningitidis and vaccines containing same
DE69423383D1 (de) Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
DK32684A (da) Fremgangsmaade til fremstilling af 26,26,26,27,27,27-hexafluor-1alfa,25-dihydroxycholesterol og mellemprodukter til brug herfor
EP0009206A3 (en) Fluor-containing 1,4-dihydropyridines, process for their preparation and their application in pharmaceuticals
DE3768720D1 (de) Verfahren zur trennung von aminosaeuren.
ATE16406T1 (de) Verfahren zur herstellung von isomaltulose (6-o- alpha-d-gluco-pyranosido-d-fructose) mit hilfe von immobilisierten bakterienzellen.
AT384032B (de) Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
ATE49185T1 (de) Verfahren zur herstellung von halogen-magnesium- alanat und dessen verwendung.
DK164628C (da) Fremgangsmaade til forbedring af ristet kaffe
DE3265664D1 (en) Process for the production of a biochemical vaccine against salmonella fevers
DE69033833D1 (de) Verfahren zur Herstellung von Butantetracarbonsäure
DE3585416D1 (de) Verfahren zur herstellung eines biologischen stoffes.
ATE92056T1 (de) Verfahren zur herstellung von 5-chlor-3chlorsulfonyl-2-thiophencarbonsaeureestern.
GB2007244A (en) Purifying Polyribosyl Ribitol Phosphate (PRP) and Vaccines containing Immunologically Active PRP
NO984206L (no) Fremgangsmaate for fremstilling av N-beskyttende D-prolinderivater
ATE116989T1 (de) Verfahren zur reinigung von hemin, neues heminderivat und verfahren zur herstellung.
FR2429765A1 (fr) Procede et agent d'adsorption pour isoler des enzymes et pour les preparer a l'etat pur
ATE37873T1 (de) Verfahren zur herstellung optisch aktiver 1,4dihydropyridine.
DE59108619D1 (de) Mikroorganismus und verfahren zur gewinnung von anthranilsäure
ATE101393T1 (de) Phenanthridinderivate, verfahren zu ihrer herstellung und mittel zur ausfuehrung des verfahrens.
SE7903233L (sv) Bensylidenestrar
DK222887D0 (da) Fremgangsmaade til fremstilling af l-aminosyrer ved fermentering af alfa-ketocarboxylsyrer
Lillich et al. Analysis of the intracellular amino acid pool and proteins from whole cells of Rhizobium japonicum
KR850003668A (ko) 피혁 폐기물의 가축사료 제조방법
UA14449A1 (uk) Спосіб отримаhhя паhтокриhа для іh'єкцій

Legal Events

Date Code Title Description
PBP Patent lapsed